Stock Market

Merck's Oral PCSK9 Inhibitor Outperforms Non-Statins in Cholesterol Lowering

By Bullbit Editorial · March 30, 2026

• WhatMerck's oral PCSK9 enlicitide demonstrates enhanced cholesterol reduction
• WhyThis is attributed to its novel mechanism of action targeting PCSK9
• SignalImproved cardiovascular outcomes are expected with this treatment
• TargetHigh-risk patients with high cholesterol are the primary target audience
• RiskPotential side effects include injection site reactions and muscle pain

More breaking news →